542 related articles for article (PubMed ID: 34779091)
1. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials.
Chaudhuri A; Ghanim H; Arora P
Diabetes Obes Metab; 2022 Mar; 24(3):365-376. PubMed ID: 34779091
[TBL] [Abstract][Full Text] [Related]
2. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
DeFronzo RA; Bakris GL
Diabetes Obes Metab; 2022 Jul; 24(7):1197-1205. PubMed ID: 35302284
[TBL] [Abstract][Full Text] [Related]
3. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
4. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
Haller H
Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
[TBL] [Abstract][Full Text] [Related]
5. Cardiorenal benefits of finerenone: protecting kidney and heart.
González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.
Albakr RB; Sridhar VS; Cherney DZI
Am J Kidney Dis; 2023 Dec; 82(6):737-742. PubMed ID: 37517546
[TBL] [Abstract][Full Text] [Related]
8. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
Morales J; Palmer BF
Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
[TBL] [Abstract][Full Text] [Related]
9. Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge.
Pradhan N; Dobre M
Curr Atheroscler Rep; 2023 Dec; 25(12):1047-1058. PubMed ID: 38038822
[TBL] [Abstract][Full Text] [Related]
10. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Agarwal R; Anker SD; Bakris G; Filippatos G; Pitt B; Rossing P; Ruilope L; Gebel M; Kolkhof P; Nowack C; Joseph A;
Nephrol Dial Transplant; 2022 May; 37(6):1014-1023. PubMed ID: 33280027
[TBL] [Abstract][Full Text] [Related]
11. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
Raj R
Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
[TBL] [Abstract][Full Text] [Related]
12. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
13. Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM.
Long A; Salvo M
Ann Pharmacother; 2022 Sep; 56(9):1041-1048. PubMed ID: 35021925
[TBL] [Abstract][Full Text] [Related]
14. New pharmacological strategies for protecting kidney function in type 2 diabetes.
Muskiet MHA; Wheeler DC; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 May; 7(5):397-412. PubMed ID: 30579729
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
Ortiz A; Ferro CJ; Balafa O; Burnier M; Ekart R; Halimi JM; Kreutz R; Mark PB; Persu A; Rossignol P; Ruilope LM; Schmieder RE; Valdivielso JM; Del Vecchio L; Zoccali C; Mallamaci F; Sarafidis P;
Nephrol Dial Transplant; 2023 Jan; 38(1):10-25. PubMed ID: 33944938
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
[TBL] [Abstract][Full Text] [Related]
17. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone.
Ortiz A; Alcázar Arroyo R; Casado Escribano PP; Fernández-Fernández B; Martínez Debén F; Mediavilla JD; Michan-Doña A; Soler MJ; Gorriz JL
Expert Rev Clin Pharmacol; 2023; 16(6):519-531. PubMed ID: 37190957
[TBL] [Abstract][Full Text] [Related]
18. Slowing Progression in CKD: DAPA CKD and Beyond.
Larmour K; Levin A
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1117-1119. PubMed ID: 33692116
[No Abstract] [Full Text] [Related]
19. [Mineralocorticoid receptor antagonists: A new therapeutic option for diabetic kidney disease].
Girerd S; Soulie M; Barrera-Chimal J; Jaisser F
Med Sci (Paris); 2023 Apr; 39(4):335-343. PubMed ID: 37094266
[TBL] [Abstract][Full Text] [Related]
20. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
